Conference abstractPublished 17 Sep 2018

Mechanistic modeling: The pathway to precision medicine

Authors: V A Shiva Ayyadurai

Massachusetts Institute of Technology, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

There are a growing and critical need for integrating molecular systems science with computation to model complex disease processes for accelerating drug discovery, drug repurposing, validation of complementary and alternative medicine (CAM) therapies and identification of efficacious multi-combination therapeutics while ensuring a personalized and precise medicine. Such needs cannot be advanced without collaborative integration of knowledge across biological disciplines. This talk will share the recent successes, through multiple case studies, in the use of CytoSolve, a computational systems biology collaboratory, developed at M.I.T., that provides an integrative approach to address these critical needs. Previous approaches, largely based on statistical techniques, have been unscalable and largely useless to scientists who seek to understand complex biological mechanisms. CytoSolve’s successes have been published in peer-reviewed journals and have received recognition in Nature for its potential to develop multicombination therapies. These successes including: FDA allowance for a multi-combination pancreatic cancer therapeutic; the Department of Defense (DoD) and the United States Pharmacopeia (USP) understanding of toxicity and adverse reaction multicombination nutritional supplements; and, modeling of rare diseases in orphan drug domains such as Neuromyelitis Optica (NMO) and Hereditary Angioedema (HAE) have inspired major nutraceutical researchers, cancer centers such as MD Anderson, National Cancer Institute and others to explore the use of CytoSolve for integrating CytoSolve’s collaboratory with modern in vitro and in vivo methods to accelerate the development of multi-combination therapeutics. This talk that will provide an introduction to a disruptive platform that will likely revolutionize the development of therapeutics in the 21st century..

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Longdom does not store it.

Try:

More from this journal

The newest in Pancreatic Disorders & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalPancreatic Disorders & Therapy
  • SubjectGastroenterology & Hepatology
  • SubjectPathology & Lab Medicine
  • BylineArticles whose byline prints “V A Shiva Ayyadurai”